MedTrace Logo

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

NCT04843943 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-14

No results posted yet for this study

Summary

This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).

Conditions

Interventions

DRUG

Sintilimab

Sintilimab: 200mg IV Q3W D1

DRUG

Bevacizumab Biosimilar

Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-05-01
Completion
2023-05-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843943 on ClinicalTrials.gov